- $1.06bn
- $1.26bn
- $272.30m
Brief: Harrow Acquires Santen’s Branded Ophthalmic Portfolio
Brief: Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance
Brief: Harrow Announces Proposed Public Offering Of Common Stock
U.S. STOCKS ON THE MOVE-DXP Enterprises, Holley, Augmedix
U.S. STOCKS ON THE MOVE-Arlo Technologies, Old Republic, Clearmind Medicine
Harrow Health drops as quarterly loss widens
Harrow Health Inc reports results for the quarter ended in March - Earnings Summary
Brief: Harrow Announces First Quarter 2023 Financial Results
Harrow Health Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Harrow To Launch FDA-Approved Iheezo™ At The 2023 American Society Of Cataract And Refractive Surgery (Ascrs) Annual Meeting
Brief: Harrow Launches Ilevro, Nevanac, And Maxidex In The U.S.
Harrow Health Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Harrow Announces New $100 Million Secured Credit Facility With Oaktree
Harrow Health Inc reports results for the quarter ended in December - Earnings Summary
Brief: Harrow Health Announces Fourth Quarter Results
Harrow Health Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Harrow Health Inc Says CMS Approved Transitional Pass-Through Reimbursement Status For IHEEZO 3%
Brief: Harrow Announces Product-Specific J-Code (J2403) For Iheezo
Brief: Harrow Closes Acquisition Of U.S. Rights To Ilevro, Nevanac, Vigamox, Maxidex, Triesence